Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for streptozotocin (compound)


PubChem
Name: Streptozocin
PubChem Compound ID: 169966
Description: An antibiotic that is produced by Stretomyces achromogenes. It is used as an antineoplastic agent and to induce diabetes in experimental animals.
Molecular formula: C8H15N3O7
Molecular weight: 265.221 g/mol
Synonyms:
2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-galactose; 37793-01-4; D-Galactose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-
DrugBank
Identification
Name: Streptozocin
Name (isomeric): DB00428
Drug Type: small molecule
Description: An antibiotic that is produced by Stretomyces achromogenes. It is used as an antineoplastic agent and to induce diabetes in experimental animals.
Brand: Streptozocinum [INN-Latin], Streptozoticin, Zanosar, STZ, Streptozocinium [Latin], STREPTOZOTOCIN, Streptozocine [INN-French], Streptozocin [Usan:Inn], STRZ
Category: Antineoplastic Agents, Antibiotics, Antibiotics, Antineoplastic
CAS number: 18883-66-4
Pharmacology
Indication: For the treatment of malignant neoplasms of pancreas (metastatic islet cell carcinoma).
Pharmacology:
Streptozocin is an antitumour antibiotic consisting of a nitrosourea moiety interposed between a methyl group and a glucosamine. Streptozocin is indicated in the treatment of metastatic islet cell carcinoma of the pancreas. Streptozocin inhibits DNA synthesis in bacterial and mammalian cells. In bacterial cells, a specific interaction with cytosine...
show more »
Mechanism of Action:
Although its mechanism of action is not completely clear, streptozocin is known to inhibit DNA synthesis, interfere with biochemical reactions of NAD and NADH, and inhibit some enzymes involved in gluconeogenesis. Its activity appears to occur as a result of formation of methylcarbonium ions, which alkylate or bind with many intracellular molecular...
show more »
Absorption: Poor oral absorption (17-25%)
Biotransformation: Primarily hepatic
Route of elimination: As much as 20% of the drug (or metabolites containing an N-nitrosourea group) is metabolized and/or excreted by the kidney.
Half Life: 5-15 minutes
Toxicity: Symptoms of overdose include nausea and vomiting, anorexia, myelosuppression; and nephrotoxicity.
Affected organisms: Humans and other mammals
Interactions
Drug interaction:
TrastuzumabTrastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.

Targets


Transporters